公开(公告)号：US11993640B2

公开(公告)日：2024-05-28

申请号：US17396577

申请日：2021-08-06

Applicant: United States Government as represented by the Department of Veterans Affairs ,  University of Miami

Inventor： Robert M. Jackson ,  Andrew V. Schally ,  Renzhi Cai

IPC: A61K38/25 ,  A61P11/00 ,  A61P35/00 ,  C07K14/60 ,  A61K38/00

CPC classification number: C07K14/60 ,  A61K38/25 ,  A61P11/00 ,  A61P35/00 ,  A61K38/00

Abstract: Described herein are compositions and methods for treating pulmonary fibrosis and cancer. The compositions include growth hormone releasing hormone peptides. The methods include reducing lung inflammation, lung scarring, reducing expression of T cell receptor complex genes as well as inhibiting tumor growth.

公开(公告)号：US11992515B2

公开(公告)日：2024-05-28

申请号：US17080268

申请日：2020-10-26

Applicant: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE

Inventor： Eid Abdullah Al Mutairy ,  Mohammed Khalid ,  Futwan Al-Mohanna

IPC: A61P11/00 ,  A61K9/00 ,  A61K38/00 ,  A61K38/17 ,  A61P9/04 ,  A61P11/08 ,  C07K14/47 ,  C12N15/52 ,  C12Q1/68 ,  C12Q1/6813 ,  C12Q1/6827

CPC classification number: A61K38/1738 ,  A61P9/04 ,  A61P11/00 ,  C07K14/4728 ,  C12N15/52 ,  A61K9/0073 ,  A61K9/0075 ,  C12Q1/6813 ,  C12Q1/6827

Abstract: The invention is directed to a method for diagnosing and treating a pulmonary lung disease by detecting a mutant S100A3 protein associated with pulmonary lung disease and by treating a subject with a functional S100A3 protein.

公开(公告)号：US20240166606A1

公开(公告)日：2024-05-23

申请号：US18421419

申请日：2024-01-24

Applicant: Shanghai AB PharmaTech Ltd.

Inventor： Zheng-Yun James ZHAN

IPC: C07D215/233 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K45/06 ,  A61P11/00 ,  A61P35/00 ,  A61P35/02 ,  C07D215/48 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12

CPC classification number: C07D215/233 ,  A61K31/44 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K45/06 ,  A61P11/00 ,  A61P35/00 ,  A61P35/02 ,  C07D215/48 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07B2200/05

Abstract: Disclosed are compounds of Formula IIIb, their stereoisomers, tautomers, deuterates, pharmacologically acceptable salts, or hydrates thereof, methods of their preparation and pharmaceutical compositions and uses comprising such compounds. The Formula IIIb compounds are useful and highly effective as multi-targeted tyrosine kinase inhibitors in treating several kinds of cancers such as pancreatic cancer, lung cancer, renal cancer, liver cancer, gastric cancer, cervical cancer, leukemia, prostatic cancer, and other antitumor uses.

公开(公告)号：US20240165116A1

公开(公告)日：2024-05-23

申请号：US18547257

申请日：2022-02-22

Applicant: Graviton Bioscience B.V.

Inventor： Samuel D. Waksal ,  Rui Wu

IPC: A61K31/506 ,  A61P11/00 ,  A61P31/14

CPC classification number: A61K31/506 ,  A61P11/00 ,  A61P31/14

Abstract: The disclosure provides compositions and methods comprising selective inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coro-navirus infections such as SARS-CoV-2, and in the treatment of seguelae resulting from the viral infection, including sequelae resulting from coronavirus infection.

公开(公告)号：US20240158471A1

公开(公告)日：2024-05-16

申请号：US18355240

申请日：2023-07-19

Applicant: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Inventor： Frans J. Walther ,  Alan J. Waring ,  Larry M. Gordon

IPC: C07K14/785 ,  A61P11/00

CPC classification number: C07K14/785 ,  A61P11/00 ,  A61K38/00

Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.

公开(公告)号：US20240156987A1

公开(公告)日：2024-05-16

申请号：US18328598

申请日：2023-06-02

Applicant: Factor Bioscience Inc.

Inventor： Matthew ANGEL ,  Christopher ROHDE

IPC: A61K48/00 ,  A61K9/00 ,  A61K31/7115 ,  A61P1/16 ,  A61P3/00 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P29/00 ,  A61P35/00 ,  C07K14/00 ,  C12N9/22

CPC classification number: A61K48/005 ,  A61K9/0019 ,  A61K31/7115 ,  A61K48/0058 ,  A61K48/0066 ,  A61P1/16 ,  A61P3/00 ,  A61P3/06 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P29/00 ,  A61P35/00 ,  C07K14/001 ,  C12N9/22 ,  C07K14/003 ,  C12N2310/20 ,  C12Y301/21

Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

公开(公告)号：US20240148839A1

公开(公告)日：2024-05-09

申请号：US18282015

申请日：2022-03-15

Applicant: KM Biologics Co., Ltd. ,  National University Corporation KUMAMOTO UNIVERSITY

Inventor： Junichi MATSUDA ,  Kento NISHIDA ,  Masaki HIRASHIMA ,  Toru MARUYAMA ,  Hiroshi WATANABE ,  Hitoshi MAEDA

IPC: A61K38/44 ,  A61K38/38 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  C07K14/765 ,  C12N9/02

CPC classification number: A61K38/44 ,  A61K38/385 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  C07K14/765 ,  C12N9/0051 ,  C12Y108/01009

Abstract: Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. The serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxin is a modified from in which at least a cysteine residue located at position 73 from the N-terminal of an amino acid sequence for the thioredoxin or located at a position equivalent to the position 73 is substituted by another amino acid residue. the modified serum albumin-thioredoxin fusion body is superior in the activity and stability thereof, is reduced in immunogenicity and has superior safety compared with a fusion body in which the thioredoxin is non-modified form.

公开(公告)号：US20240148795A1

公开(公告)日：2024-05-09

申请号：US18548803

申请日：2022-03-03

Applicant: METCELA INC.

Inventor： Takahiro IWAMIYA

IPC: A61K35/33 ,  A61P11/00 ,  A61P43/00

CPC classification number: A61K35/33 ,  A61P11/00 ,  A61P43/00

Abstract: A fibroblast highly expressing ADM and/or HHEX has been found as a cell having lymphangiogenesis ability, and a procedure for treating fibrosis, a procedure for ameliorating a condition of lymphangiogenesis ability reduced, and procedures for modulating homeostasis of a tissue fluid, transport of lipid and/or vitamin, and immunological surveillance, and for treating organ failure, by use of a pharmaceutical composition including the fibroblast, have been found. In addition, it has been found that an adult-derived fibroblast highly expressing ADM and increasing expression of VCAM-1 is obtained by culturing a human fibroblast with a medium to which TNF-α and IL-4 are added and it has been found that a fibroblast highly expressing ADM is provided, and a procedure for treating a pulmonary disease by use of the fibroblast has been found.

公开(公告)号：US11963965B2

公开(公告)日：2024-04-23

申请号：US17130580

申请日：2020-12-22

Applicant: National Jewish Health

Inventor： Preston E. Bratcher ,  Pamela L. Zeitlin

IPC: A61K31/558 ,  A61K31/352 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/502 ,  A61K45/06 ,  A61P11/00

CPC classification number: A61K31/558 ,  A61K31/352 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/502 ,  A61K45/06 ,  A61P11/00

Abstract: Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR)-mediated disease, such as cystic fibrosis, in patients with residual function mutations.

公开(公告)号：US20240124570A1

公开(公告)日：2024-04-18

申请号：US18464174

申请日：2023-09-08

Applicant: University of Miami

Inventor： Juan Pablo De Rivero Vaccari ,  Robert W. Keane ,  W. Dalton Deitrich ,  Helen M. Bramlett

IPC: C07K16/24 ,  A61K31/727 ,  A61K39/395 ,  A61P11/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/28 ,  A61P29/00 ,  A61P37/06 ,  C07K16/18

CPC classification number: C07K16/24 ,  A61K31/727 ,  A61K39/39541 ,  A61K39/3955 ,  A61P11/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/28 ,  A61P29/00 ,  A61P37/06 ,  C07K16/18 ,  A61K2039/505

Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for detecting and treating early-stage Alzheimer's disease as well as other inflammatory neurologic conditions.